Lp(a) and Cardiovascular Risk: Advancing Awareness, Testing, and Management in Clinical Practice : Episode 8

Opinion

Video

April 14, 2025

The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

Author(s):

Experts discuss how guideline recommendations influence formulary decisions regarding preventive measures like lipoprotein(a) (Lp[a]) testing, exploring the varying recommendations from organizations such as the American Association of Clinical Endocrinologists, the American Heart Association, and the National Lipid Association (NLA), and how these align with recent guidance from Europe and Canada.

EP: 1.Lp(a) in ASCVD and Guideline Recommendations

EP: 2.Introduction and Burden of Atherosclerotic Disease and Aortic Stenosis

EP: 3.The Role of Prevention in the Management of Atherosclerotic Disease and Aortic Stenosis

EP: 4.Studying the Association Between Elevated Lp(a) Levels and Risk of Atherosclerotic Disease

EP: 5.Lp(a) Levels: A Continuous Relationship With ASCVD Levels and Consistent Throughout a Lifetime

EP: 6.How the Genetic Nature of Lp(a) Levels Influences Screening

EP: 7.A Case Study of Elevated Lp(a) Levels and Increased ASCVD Risk

Now Viewing

EP: 8.The Role of Management Guidelines in Formulary Decision-Making and Recent Lp(a) Recommendations

EP: 9.Evidence Supporting 2024 Guidance for Lp(a) Testing

EP: 10.Factoring Cost, Recommendations, and Evidence Into Formulary Decisions about Lp(a) Testing

EP: 11.Assessing the Quality of Recommendations and Making Clinical Decisions About Lp(a) Testing

EP: 12.FDA-Approved and Pipeline Treatments for Elevated Lp(a) Levels

EP: 13.The Benefits of Lp(a) Testing in the Absence of Lp(a)-Lowering Therapies

EP: 14.Results of Lp(a) Testing to Modify Risk Assessment and Optimize Treatment

EP: 15.Lp(a) Testing: Prevalence and Strategies to Improve Uptake

EP: 16.Implementing Lp(a) Testing in Health Systems: Lessons From Real-World Experience

EP: 17.Implementing Lp(a) Testing: Learning From LDL Testing and Considering Value-Based Care Models

EP: 18.Present and Looking to the Future: Lp(a) Testing and Atherosclerotic Disease Management

Video content above is prompted by the following:

How do guideline recommendations factor into formulary decisions about preventive measures like Lp(a) testing?
In the introduction, I mentioned that there are several national and international guidelines offering slightly different recommendations about when Lp(a) should be measured. Among these are statements from the American Association of Clinical Endocrinologists and American College of Endocrinology, the American Heart Association, and the American College of Cardiology from 2022 or earlier, which recommend Lp(a) measurement in patients with a family history of atherosclerotic cardiovascular disease and/or elevated Lp(a) levels. However, in 2024, the NLA recommended that Lp(a) be measured in all adults. How does this recommendation align with recent guidance from Europe and Canada?

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

June 3rd 2025

Gaps in the Coordination of Care for Older Adults With or at Risk for Cardiovascular Disease

Lisa M. Kern, MD, MPH Joselyne E. Aucapina Samprit Banerjee, PhD Joanna B. Ringel, MPH Jonathan N. Tobin, PhD Semhar Fisseha, MPH Helena Meiri, MA, RN Madeline R. Sterling, MD, MPH Kurt C. Stange, MD, PhD Monika M. Safford, MD Paul N. Casale, MD, MPH

Older adults with cardiovascular disease (CVD) or CVD risk factors report that gaps in communication among their providers are common and hazardous.

May 30th 2024

From Polypharmacy to Personalized Care: Dr Nihar Desai Discusses Holistic Cardiovascular Care

Giuliana Grossi

In this episode of Managed Care Cast, Nihar Desai, MD, MPH, cardiologist and vice chief of Cardiology at the Yale School of Medicine, discusses therapies for cardiovascular conditions as they relate to patient adherence, polypharmacy, and health access.

May 16th 2025

Predicting Mortality Risk Using the PREVENT Equation Across Diverse Racial Groups

Ofer Kobo, MD Martin K. Rutter, MD Shivani Misra, PhD Erin D. Michos, MD, MHS Phyo K. Myint, MD Ariel Roguin, MD, PhD Louise Y. Sun, MD Mamas A. Mamas, MD

This study validates the Predicting Risk of CVD Events (PREVENT) score across diverse racial and ethnic populations, highlighting its effectiveness in predicting cardiovascular risk and mortality, regardless of race or ethnicity.

May 10th 2022

For National Women’s Health Week, One Company Emphasizes Cardiovascular Risk Management

On this episode of Managed Care Cast, we speak with Joanne Armstrong, MD, MPH, vice president and chief medical officer for Women’s Health and Genomics at CVS Health, on the distinct pathophysiology of cardiovascular disease in women and how her own health experiences have influenced her perspective on cardiovascular disease management.

Nurse using stethoscope on older patient | Image credit: InsideCreativeHouse – stock.adobe.com

May 9th 2025

Is Frailty Index the Most Accurate Predictor of CVD?

Hayden E. Klein

A study comparing biological aging indicators found that Rockwood Frailty Index was a stronger predictor of cardiovascular disease (CVD) than leukocyte telomere length in adults without prior CVD.